Conclusion: GLP-1 RAs and co-agonists are efficacious for weight loss, with reported safety concerns predominantly gastrointestinal in nature, when used among adults with overweight or obesity and without diabetes.
PubMed 39761578 ↗Liraglutide
Also known as Saxenda, Victoza
The short answer. There isn't much data on Liraglutide yet — 15 mentions, 7 with a clear outcome — so treat these numbers as anecdotal. It is most often used for weight loss: 100% of 5 reports say that improved. It is well studied — 418 meta-analyses on PubMed.
From 15 mentions in total — the rest didn't say how it went and aren't counted.
What Liraglutide does, according to users
Of the people who reported each effect, the share who said it got better.
2 more with fewer than 3 reports
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 418 meta-analyses on PubMed ↗ · 560 randomized trials ↗
Conclusion: The proportion of weight regained was proportional to the amount originally lost. Meaning: Discontinuation of GLP-1RA treatment leads to weight regain, regardless of lifestyle interventions, and should therefore be considered a chronic therapy to prevent weight regain and associated undesirable outcomes related to obesity.
PubMed 40186344 ↗Conclusion: GLP-1RAs decreased liver fat deposition and improved histological steatosis, hepatocellular ballooning, and lobular inflammation, without worsening of fibrosis in MASLD and MASH.
PubMed 40489581 ↗Conclusion: The current systematic review showed that semaglutide provides more QALYs and creates more costs in comparison with phentermine-topiramate, phentermine, and naltrexone-bupropion. Semaglutide may be cost-effective with substantial cost reduction. Semaglutide appears to be cost-effective versus diet and exercise (D&E) and liraglutide but it was not cost-effective versus sleeve gastrectomy, endoscopic sleeve gastroplasty, and gastric bypass.
PubMed 39254692 ↗514 human trials on ClinicalTrials.gov test Liraglutide — 364 completed, 25 recruiting now. See all on ClinicalTrials.gov ↗
- Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome · Polycystic Ovary · 2025
- LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes · Type 2 Diabetes Mellitus, Mild Cognitive Impairment · 2026
- GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation · Alzheimer Disease, Diabetes Mellitus Type 2 · 2026
What government agencies say
Official records from US, Canadian and EU regulators, each linked to its source.
Boxed warning (the FDA's strongest label warning): “RISK OF THYROID C-CELL TUMORS Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether liraglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in…”
3 recalls of products named for Liraglutide. Most recent:
- 2026-05-27 · Class II: Presence of particulate matter: a white thread-like structure in the cartridge record ↗
- 2021-04-21 · Class II: Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of… record ↗
Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗
49,117 adverse-event reports mention Liraglutide. Most often reported:
- Nausea · 7,176
- Blood glucose increased · 3,907
- Vomiting · 3,515
- Diarrhoea · 3,376
- Pancreatitis · 2,329
- Weight decreased · 2,115
Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗
NIH has funded 3 research projects with Liraglutide in the title, $3,300,308 in total (2012–2026). NIH RePORTER ↗
Plain-language guides from the US government: MedlinePlus: Liraglutide Injection ↗
Dosage people report
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“During my journey I used Liraglutide, Sema and tried Tirz in the beginning - it really helped”
“I used saxenda to loose weight, but I noticed it helped me with online shopping”
“I see others do incredibly well on the "inferior" Liraglutide.”
Top discussions (5)
- all the "soft" and "hardcore" biohacks gathered in one simplified list: ↗
- what supplement stack do you recommend for 35 years old male who's overweight and have insulin resistance? ↗
- GLP-1 receptors are everywhere in your body, not just your pancreas. Here's what that means for benefits beyond weight loss. ↗
- Ozempic's Older Sibling Might Slow Down Alzheimer's ↗
- Peptides and weight loss ↗
Other options for weight loss
Sources
- User reports: 15 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
- FDA drug label (DailyMed) ↗
- FDA adverse-event reports (FAERS) ↗
- FDA recalls ↗
- LiverTox (NIH) ↗
- MedlinePlus (NIH) ↗
- NIH RePORTER ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate